Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300943 | 0.91 | BRD4 (0.35) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6299516 | 0.88 | MAOA (0.37) | BRD4LTB4RLTB4R2 | |
| SCHEMBL6300288 | 0.88 | BRD4 (0.38) | BRD4LTB4RLTB4R2MRGPRX4NPC1 | |
| SCHEMBL6306985 | 0.87 | LTB4R (0.34) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6307052 | 0.86 | BRD4 (0.37) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6299535 | 0.86 | MAOA (0.36) | BRD4LTB4RLTB4R2 | |
| SCHEMBL6301972 | 0.86 | LTB4R (0.37) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6299367 | 0.85 | LTB4R (0.35) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6300122 | 0.85 | MAOB (0.39) | BRD4LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL6302244 | 0.85 | BRD4 (0.35) | BRD4LTB4RLTB4R2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | claimed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | BRD4 2102/4885LTB4R 1427/4885LTB4R2 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.